LONDON (Reuters) – Eli Lilly has won a patent case
in the Court of Appeal in London over its blockbuster Alimta
lung cancer drug, boosting prospects for future sales and
dealing a blow to generic challenger Actavis.
Alimta generated worldwide sales of $2.79 billion for Lilly
last year, making the medicine its biggest-selling product.
LONDON (Reuters) – AstraZeneca has lost a second senior executive in a fortnight with the departure of its respiratory and inflammatory medicines head James Ward-Lilley to become chief executive of lung drug specialist Vectura.
His departure follows the exit earlier this month of Briggs Morrison, AstraZeneca’s former chief medical officer and head of late-stage drug development, who moved on to become CEO of privately owned cancer drug firm Syndax.
LONDON, June 17 (Reuters) – Scientists have discovered a new
anti-malarial compound that could treat patients with a single
$1 dose, including those with strains of the mosquito-borne
disease that are resistant to current drugs.
Although it is still years from reaching the market, results
from tests conducted on human blood in the laboratory and in
live mice suggest it is highly potent, researchers reported in
the journal Nature on Wednesday.
LONDON (Reuters) – Drugmakers’ plans to conduct vast clinical trials to test and hopefully validate the first Ebola vaccines have been thwarted by success in beating back the deadly epidemic in West Africa.
GlaxoSmithKline, Merck and Johnson & Johnson are struggling to recruit volunteers with enough exposure to the disease to prove whether their vaccines are doing the job and preventing infection.
LONDON (Reuters) – Imports of energy and life-saving medicines top the list of products in jeopardy if Greece defaults on its debt and moves closer to exiting the euro zone.
The threat to vital supplies is increasingly exercising policymakers, companies and traders as an impasse in negotiations between Athens and international creditors provokes alarm in financial markets.
LONDON (Reuters) – Three years after the mysterious MERS virus first emerged in humans, scientists and drugmakers say there is no excuse for not having a vaccine that could have protected those now falling sick and dying in South Korea.
The facts behind the coronavirus that causes Middle East Respiratory Syndrome (MERS) have been slow to emerge, partly due to a secretive response in Saudi Arabia, which has suffered an outbreak stretching back to 2012.
LONDON (Reuters) – A pioneering gene therapy for sickle cell disease is working well so far for a 13-year-old French boy with the hereditary blood disorder, researchers said on Saturday, in a boost for the technology to fix faulty genes.
He is the first patient with severe sickle cell disease (SCD) to be treated with Bluebird Bio’s LentiGlobin BB305 product, which the U.S. biotech company believes could cure the disorder.
LONDON, June 10 (Reuters) – AstraZeneca’s chief
medical officer and head of global late-stage drug development
Briggs Morrison is to leave the company, creating a gap at the
top of the group’s research operations.
A spokeswoman said on Wednesday Morrison was departing to
become chief executive of an unlisted venture capital-backed
drugmaker in the United States, adding there had been no
disagreement with other top managers at AstraZeneca.
SHANGHAI/LONDON, June 10 (Reuters) – Years of pouring money
into its laboratories, wooing scientists home from overseas and
urging researchers to publish and patent is starting to give
China a competitive edge in biotechnology, a strategic field it
sees as ripe for “indigenous innovation.”
The vast resources China can throw at research and
development – overall funding more than quadrupled to $191
billion in 2005-13 and the Thousand Talents Program has
repatriated scientists – allow China to jump
quickly on promising new technologies, often first developed
June 9 (Reuters) – A Canadian team hopes to revive a heart
drug ditched by Roche three years ago by running a
major clinical trial targeting only those patients with the
right genetic profile to benefit from its ability to boost
The Swiss drugmaker, which has licensed rights to
dalcetrapib to Quebec-based DalCor Pharmaceuticals, said on
Tuesday it would provide a companion diagnostic for use in the
Phase III study.